BR0212256A - Proteìnas de fusão de transferrina modificadas - Google Patents
Proteìnas de fusão de transferrina modificadasInfo
- Publication number
- BR0212256A BR0212256A BR0212256-1A BR0212256A BR0212256A BR 0212256 A BR0212256 A BR 0212256A BR 0212256 A BR0212256 A BR 0212256A BR 0212256 A BR0212256 A BR 0212256A
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- transferrin fusion
- modified transferrin
- transferrin
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Abstract
"PROTEìNAS DE FUSãO DE TRANSFERRINA MODIFICADAS". A presente invenção refere-se a proteínas de fusão modificadas de transferrina e proteínas terapêuticas ou peptídeos com meia-vida de soro ou estabilidade de soro aumentadas são descritas. As proteínas de fusão preferidas incluem aquelas modificadas de modo que a porção de transferrina não exiba nenhuma ou reduzida glicosilação, ligação a ferro e/ou ligação ao receptor de transferrina.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31574501P | 2001-08-30 | 2001-08-30 | |
US33405901P | 2001-11-30 | 2001-11-30 | |
PCT/US2002/027637 WO2003020746A1 (en) | 2001-08-30 | 2002-08-30 | Modified transferrin fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0212256A true BR0212256A (pt) | 2004-08-31 |
Family
ID=26980047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0212256-1A BR0212256A (pt) | 2001-08-30 | 2002-08-30 | Proteìnas de fusão de transferrina modificadas |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040023334A1 (pt) |
EP (1) | EP1427750B1 (pt) |
JP (2) | JP2005508623A (pt) |
KR (1) | KR20040059490A (pt) |
CN (1) | CN1628126A (pt) |
AT (1) | ATE490969T1 (pt) |
AU (1) | AU2002323501C1 (pt) |
BR (1) | BR0212256A (pt) |
CA (1) | CA2457520A1 (pt) |
DE (1) | DE60238541D1 (pt) |
DK (1) | DK1427750T3 (pt) |
IL (1) | IL160289A0 (pt) |
MX (1) | MXPA04001804A (pt) |
NZ (1) | NZ531207A (pt) |
RU (1) | RU2004109222A (pt) |
WO (1) | WO2003020746A1 (pt) |
ZA (1) | ZA200401079B (pt) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
AU2002323501C1 (en) * | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
ES2347144T3 (es) * | 2002-08-30 | 2010-10-26 | Biorexis Pharmaceutical Corporation | Proteinas de fusion de la transferrina modificada que comprenden dominos aino o carboxilo de transferrina duplicados. |
AU2003270010A1 (en) * | 2002-08-30 | 2004-03-19 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
US20060105387A1 (en) * | 2002-08-30 | 2006-05-18 | Prior Christopher P | Transferrin fusion proteins libraries |
US7592306B2 (en) * | 2002-12-10 | 2009-09-22 | Agennix, Inc. | Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20070060512A1 (en) * | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
US7379700B2 (en) * | 2003-05-06 | 2008-05-27 | Canon Kabushiki Kaisha | Image reading apparatus with rotatable internal and external guides |
US8105615B2 (en) * | 2003-06-06 | 2012-01-31 | Agennix Incorporated | Lactoferrin as an adjuvant in cancer vaccines |
JP2007512001A (ja) * | 2003-08-28 | 2007-05-17 | バイオレクシス ファーマシューティカル コーポレイション | Epoミメティックペプチドおよび融合タンパク質 |
US20060205037A1 (en) * | 2003-08-28 | 2006-09-14 | Homayoun Sadeghi | Modified transferrin fusion proteins |
CN1938333A (zh) * | 2003-12-03 | 2007-03-28 | 达尔塔生物技术有限公司 | 白介素-11融合蛋白 |
WO2006009825A1 (en) * | 2004-06-17 | 2006-01-26 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
US7183381B2 (en) * | 2004-10-26 | 2007-02-27 | Agennix, Inc. | Composition of lactoferrin related peptides and uses thereof |
JP2008546392A (ja) * | 2005-06-17 | 2008-12-25 | バイオレクシス ファーマシューティカル コーポレーション | 固定されたトランスフェリン融合タンパク質ライブラリー |
JP4976412B2 (ja) | 2005-12-01 | 2012-07-18 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 |
EP2046826B1 (en) | 2006-07-24 | 2011-09-14 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
KR100744419B1 (ko) | 2006-08-03 | 2007-07-30 | 동부일렉트로닉스 주식회사 | 반도체 소자 및 반도체 소자의 제조 방법 |
EP2114999A2 (en) | 2006-12-12 | 2009-11-11 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
JP2010535484A (ja) * | 2007-08-08 | 2010-11-25 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | トランスフェリン変異体と複合体 |
PT2277890E (pt) * | 2008-05-23 | 2016-03-31 | Daiichi Sankyo Co Ltd | Péptido capaz de prolongar o semi-período de vida do péptido de interesse no plasma |
US8557292B2 (en) | 2008-08-13 | 2013-10-15 | California Institute Of Technology | Carrier nanoparticles and related compositions, methods and systems |
EP2617733A1 (en) | 2009-02-06 | 2013-07-24 | Novozymes Biopharma DK A/S | Purification process |
EP2216341A1 (en) | 2009-02-10 | 2010-08-11 | Novozymes Biopharma UK Limited | Transferrin variants and conjugates |
US9644197B2 (en) * | 2010-06-04 | 2017-05-09 | Sk Chemicals Co., Ltd. | Fusion protein having factor VII activity |
KR101853405B1 (ko) * | 2010-10-20 | 2018-05-02 | 주식회사 티움바이오 | 인자 ix 활성을 갖는 융합 단백질 |
KR102099462B1 (ko) | 2010-11-30 | 2020-04-10 | 제넨테크, 인크. | 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도 |
EP2648756A4 (en) * | 2010-12-10 | 2016-06-08 | California Inst Of Techn | TARGETING RENAL MESANGIOM WITH DEFINED DIAMETER NANOPARTICLES |
CN103998470A (zh) | 2011-08-17 | 2014-08-20 | 科罗拉多大学董事会法人团体 | 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法 |
IL283215B1 (en) | 2011-11-16 | 2024-01-01 | Adrenomed Ag | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment and pharmaceutical preparations containing them |
JP6193872B2 (ja) | 2011-11-16 | 2017-09-06 | アドレノメト アクチェンゲゼルシャフト | 慢性又は急性疾患に罹患している患者の体液平衡を調整するための抗アドレノメデュリン(ADM)抗体、抗ADM抗体フラグメント又は抗ADM非Ig足場 |
ES2751492T3 (es) | 2011-11-16 | 2020-03-31 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o armazón no Ig anti-ADM para uso en la terapia de una enfermedad aguda o una afección aguda de un paciente para estabilizar la circulación |
MY178654A (en) | 2011-11-16 | 2020-10-20 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy |
ES2494190T3 (es) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo |
PT3553084T (pt) | 2011-11-16 | 2023-02-17 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou esqueleto não-ig anti-adm para prevenção ou redução de disfunção de órgãos ou insuficiência de órgãos num paciente possuindo uma doença crónica ou aguda ou condição aguda |
CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
JP6401702B2 (ja) | 2012-09-07 | 2018-10-10 | ザ・ガバナーズ・オブ・ザ・ユニバーシティー オブ・アルバータ | 炎症性肝疾患の診断のための方法および組成物 |
CA2886779C (en) | 2012-10-02 | 2022-11-01 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction |
CN113759128A (zh) * | 2012-12-04 | 2021-12-07 | 霍夫曼-拉罗奇有限公司 | 心力衰竭疗法的选择中的生物标记物 |
RU2677895C2 (ru) | 2013-01-08 | 2019-01-22 | Сфинготек Гмбх | Уровни гормона роста натощак в качестве прогностического маркера сердечно-сосудистого риска |
WO2014124540A1 (en) * | 2013-02-15 | 2014-08-21 | The Royal Institute For The Advancement Of Learning/Mcgill University | Modified ingap peptides for treating diabetes |
CA2901226C (en) * | 2013-02-18 | 2020-11-17 | Vegenics Pty Limited | Vascular endothelial growth factor binding proteins |
US9132097B2 (en) | 2013-03-01 | 2015-09-15 | California Institute Of Technology | Nanoparticles stabilized with nitrophenylboronic acid compositions |
US9468681B2 (en) | 2013-03-01 | 2016-10-18 | California Institute Of Technology | Targeted nanoparticles |
US20160039877A1 (en) | 2013-03-15 | 2016-02-11 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
RU2673455C2 (ru) | 2013-03-20 | 2018-11-27 | Сфинготек Гмбх | Адреномедуллин для направленной терапии по снижению кровяного давления |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
US20160097781A1 (en) | 2014-10-01 | 2016-04-07 | Sphingotec Gmbh | Method for stratifying a female subject for hormone replacement therapy |
EP3970748A1 (en) | 2014-12-24 | 2022-03-23 | NexImmune, Inc. | Nanoparticle compositions and methods for immunotherapy |
EP3286570A1 (en) | 2015-04-24 | 2018-02-28 | SphingoTec GmbH | A method for predicting the risk of incidence of chronic kidney disease |
EP3795609B1 (en) | 2015-07-01 | 2024-04-03 | California Institute of Technology | Cationic mucic acid polymer-based delivery systems |
EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
SG10202004259PA (en) | 2015-11-19 | 2020-06-29 | Asclepix Therapeutics Llc | Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations |
RU2614141C1 (ru) * | 2015-12-28 | 2017-03-23 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) | Способ прогнозирования парафарингиального абсцесса при остром паратонзиллите |
EP3998281A1 (en) | 2016-02-05 | 2022-05-18 | Orionis Biosciences BV | Cd8 binding agents |
EP3426278B1 (en) | 2016-03-07 | 2024-01-03 | Vib Vzw | Cd20 binding single domain antibodies |
CH713803B1 (de) | 2016-04-21 | 2023-08-15 | 4TEEN4 Pharmaceuticals GmbH | Verfahren zur Diagnose durch Bestimmung von DPP3, Hemmer der Aktivität von DPP3 und Zusammensetzung mit einem Hemmer. |
WO2017194782A2 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Therapeutic targeting of non-cellular structures |
JP7105200B2 (ja) | 2016-05-13 | 2022-07-22 | オリオニス バイオサイエンシズ ビーブイ | 標的突然変異体インターフェロン-ベータおよびその使用 |
MA45493A (fr) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
CN109716136B (zh) | 2016-07-08 | 2023-09-22 | 斯弗因高泰克有限公司 | 肾上腺髓质素用于评估急性心力衰竭患者的充血 |
CN110177563A (zh) | 2016-10-04 | 2019-08-27 | 阿斯克雷佩西治疗公司 | 用于激活tie2信号传导的化合物和方法 |
EP3309550A1 (en) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
ES2917000T3 (es) | 2016-10-24 | 2022-07-06 | Orionis Biosciences BV | Interferón-gamma mutante diana y usos del mismo |
EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
CA3046850A1 (en) | 2016-12-16 | 2018-06-21 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
US10906985B2 (en) | 2017-02-06 | 2021-02-02 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
CN110678757B (zh) | 2017-05-30 | 2024-04-05 | 斯弗因高泰克有限公司 | 诊断或监测肾功能或诊断肾功能障碍的方法 |
US20210155674A1 (en) * | 2017-06-30 | 2021-05-27 | Western University Of Health Sciences | Factor ix-transferrin fusion proteins |
US11674959B2 (en) | 2017-08-03 | 2023-06-13 | The Johns Hopkins University | Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors |
EP4159230A1 (en) | 2017-09-25 | 2023-04-05 | AdrenoMed AG | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
CN111480076A (zh) | 2017-10-18 | 2020-07-31 | 艾德里诺医药公司 | 抗肾上腺髓质素(adm)结合剂治疗下的疗法监测 |
JP7411546B2 (ja) | 2017-10-24 | 2024-01-11 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 初回心血管イベントの予測のためのセレノプロテインp |
WO2019081595A2 (en) | 2017-10-25 | 2019-05-02 | Sphingotec Therapeutics Gmbh | DPP3 BINDER DIRECTED TO AND BINDING SPECIFIC DPP3 EPITOPES AND USE THEREOF IN THE PREVENTION OR TREATMENT OF OXIDATIVE STRESS ASSOCIATED DISEASES / CONDITIONS |
US11896643B2 (en) | 2018-02-05 | 2024-02-13 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
US20210302440A1 (en) | 2018-02-08 | 2021-09-30 | Sphingotec Gmbh | Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia |
EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
SG11202105176QA (en) | 2018-12-20 | 2021-06-29 | Sphingotec Gmbh | Selenoprotein p in heart failure |
JP2022516438A (ja) | 2018-12-21 | 2022-02-28 | 4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アンジオテンシン受容体アゴニストおよび/またはその前駆体による治療のための治療ガイドおよび/または治療モニタリング |
CN113661175A (zh) | 2019-02-15 | 2021-11-16 | 整体分子公司 | 包含共同轻链的抗体及其用途 |
KR20210128443A (ko) | 2019-02-15 | 2021-10-26 | 인테그럴 몰큘러 인코포레이티드 | 클라우딘 6 항체 및 이의 용도 |
CN114364984A (zh) | 2019-08-15 | 2022-04-15 | 思芬构技术有限公司 | 一种诊断或监测儿科患者的肾功能或诊断肾功能障碍的方法 |
MX2022002432A (es) | 2019-08-30 | 2022-06-02 | 4TEEN4 Pharmaceuticals GmbH | Orientacion terapeutica y/o monitoreo terapeutico para el tratamiento de choques. |
US20220340628A1 (en) * | 2019-09-20 | 2022-10-27 | MVRIX Co., Ltd. | Tag protein for increasing water solubility and heat stability of target protein, and fusion protein comprising same |
EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
AU2021228207A1 (en) | 2020-02-27 | 2022-10-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock |
AU2021227279A1 (en) | 2020-02-27 | 2022-10-20 | Adrenomed Ag | Anti-adrenomedullin (ADM) binder for use in therapy of patients in shock |
WO2021170876A1 (en) | 2020-02-27 | 2021-09-02 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
EP4121771A1 (en) | 2020-03-16 | 2023-01-25 | AdrenoMed AG | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
EP4121763A1 (en) | 2020-03-16 | 2023-01-25 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
GB202004514D0 (en) | 2020-03-27 | 2020-05-13 | Inst De Medicina Molecular Joaeo Lobo Antunes | Treatment of Immunosuppressive Cancer |
EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
US11180534B1 (en) * | 2021-06-04 | 2021-11-23 | Morehouse School Of Medicine | Compositions and methods for treating SARS-CoV-2 infections |
EP4356139A1 (en) | 2021-06-18 | 2024-04-24 | sphingotec GmbH | A method for predicting sepsis and septic shock |
WO2023275099A1 (en) | 2021-06-29 | 2023-01-05 | Berysol Gmbh | Composite biomarker for the identification of selenium deficiency in a bodily fluid |
WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
WO2024008755A1 (en) | 2022-07-04 | 2024-01-11 | Vib Vzw | Blood-cerebrospinal fluid barrier crossing antibodies |
WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
WO2024077118A2 (en) | 2022-10-06 | 2024-04-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2001A (en) * | 1841-03-12 | Sawmill | ||
US4289689A (en) * | 1980-03-14 | 1981-09-15 | Hoffmann-La Roche Inc. | Preparation of homogeneous human fibroblast interferon |
WO1982002715A1 (fr) * | 1981-02-04 | 1982-08-19 | Sugano Haruo | Gene d'interferon (beta)humain |
US4816449A (en) * | 1984-08-09 | 1989-03-28 | Immunetech Pharmaceuticals | Immunotherapeutic anti-inflammatory peptide agents |
US5026651A (en) * | 1985-04-25 | 1991-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the production of human transferrin |
US5262177A (en) * | 1986-02-07 | 1993-11-16 | Oncogen | Recombinant viruses encoding the human melanoma-associated antigen |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5091513A (en) * | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
PT88641B (pt) | 1987-10-02 | 1993-04-30 | Genentech Inc | Metodo para a preparacao de uma variante de adesao |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5571691A (en) * | 1989-05-05 | 1996-11-05 | Baylor College Of Medicine | Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
US6066469A (en) * | 1990-03-08 | 2000-05-23 | Ferro Dynamics, Inc. | Cloning, expression, and uses of human lactoferrin |
US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5986067A (en) * | 1991-02-08 | 1999-11-16 | The University Of Vermont And State Agricultural College | Recombinant transferrins, transferrin half-molecules and mutants thereof |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
EP0603187A4 (en) * | 1991-05-31 | 1995-08-30 | Us Health | Human lactoferrin. |
FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
ZA932568B (en) * | 1992-04-24 | 1993-11-12 | Baylor College Midecine A Non | Production of recombinant human lactoferrin |
EP0599303A3 (en) * | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
US5843882A (en) * | 1995-04-27 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides |
US5817789A (en) | 1995-06-06 | 1998-10-06 | Transkaryotic Therapies, Inc. | Chimeric proteins for use in transport of a selected substance into cells |
US5849293A (en) * | 1996-01-11 | 1998-12-15 | Cornell Research Foundation, Inc. | Use of human transferrin in controlling insulin levels |
US7235627B2 (en) * | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6258782B1 (en) * | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6329336B1 (en) * | 1999-05-17 | 2001-12-11 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
US6380362B1 (en) * | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
US6420346B1 (en) * | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
AU2002323501C1 (en) * | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
ES2347144T3 (es) * | 2002-08-30 | 2010-10-26 | Biorexis Pharmaceutical Corporation | Proteinas de fusion de la transferrina modificada que comprenden dominos aino o carboxilo de transferrina duplicados. |
US20060105387A1 (en) * | 2002-08-30 | 2006-05-18 | Prior Christopher P | Transferrin fusion proteins libraries |
US20060205037A1 (en) * | 2003-08-28 | 2006-09-14 | Homayoun Sadeghi | Modified transferrin fusion proteins |
-
2002
- 2002-08-30 AU AU2002323501A patent/AU2002323501C1/en not_active Ceased
- 2002-08-30 RU RU2004109222/13A patent/RU2004109222A/ru not_active Application Discontinuation
- 2002-08-30 IL IL16028902A patent/IL160289A0/xx unknown
- 2002-08-30 DE DE60238541T patent/DE60238541D1/de not_active Expired - Lifetime
- 2002-08-30 US US10/231,494 patent/US20040023334A1/en not_active Abandoned
- 2002-08-30 JP JP2003525016A patent/JP2005508623A/ja active Pending
- 2002-08-30 KR KR10-2004-7002867A patent/KR20040059490A/ko not_active Application Discontinuation
- 2002-08-30 EP EP02757486A patent/EP1427750B1/en not_active Expired - Lifetime
- 2002-08-30 CN CNA028216377A patent/CN1628126A/zh active Pending
- 2002-08-30 DK DK02757486.2T patent/DK1427750T3/da active
- 2002-08-30 WO PCT/US2002/027637 patent/WO2003020746A1/en active Application Filing
- 2002-08-30 BR BR0212256-1A patent/BR0212256A/pt not_active IP Right Cessation
- 2002-08-30 MX MXPA04001804A patent/MXPA04001804A/es active IP Right Grant
- 2002-08-30 CA CA002457520A patent/CA2457520A1/en active Pending
- 2002-08-30 NZ NZ531207A patent/NZ531207A/en not_active IP Right Cessation
- 2002-08-30 AT AT02757486T patent/ATE490969T1/de not_active IP Right Cessation
-
2004
- 2004-02-10 ZA ZA2004/01079A patent/ZA200401079B/en unknown
-
2009
- 2009-08-27 JP JP2009197098A patent/JP2010004891A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
KR20040059490A (ko) | 2004-07-05 |
IL160289A0 (en) | 2004-07-25 |
MXPA04001804A (es) | 2005-03-07 |
EP1427750A4 (en) | 2006-01-18 |
CA2457520A1 (en) | 2003-03-13 |
CN1628126A (zh) | 2005-06-15 |
DE60238541D1 (de) | 2011-01-20 |
ZA200401079B (en) | 2005-05-25 |
EP1427750B1 (en) | 2010-12-08 |
RU2004109222A (ru) | 2005-10-20 |
EP1427750A1 (en) | 2004-06-16 |
JP2010004891A (ja) | 2010-01-14 |
AU2002323501B2 (en) | 2009-03-26 |
ATE490969T1 (de) | 2010-12-15 |
WO2003020746A1 (en) | 2003-03-13 |
US20040023334A1 (en) | 2004-02-05 |
JP2005508623A (ja) | 2005-04-07 |
DK1427750T3 (da) | 2011-02-14 |
NZ531207A (en) | 2006-08-31 |
AU2002323501C1 (en) | 2010-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0212256A (pt) | Proteìnas de fusão de transferrina modificadas | |
WO2004020404A3 (en) | Modified transferin-antibody fusion proteins | |
DE60333306D1 (de) | Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen | |
WO2004020405A3 (en) | Modified transferrin fusion proteins | |
ATE316982T1 (de) | Mehrere zytokin-antikörper komplexen | |
WO2007047504A3 (en) | Natriuretic peptide modified transferrin fusion proteins | |
DK1088084T3 (da) | Erythropoietin analog-humant serumalbumin fusionsprotein | |
YU9404A (sh) | Multimerna, usmerena kontrastna sredstva na bazi peptida | |
CY1105895T1 (el) | Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης | |
MXPA02004666A (es) | Gelatinas recombinantes. | |
PL369741A1 (en) | Immunocytokines with modulated selectivity | |
DE50012863D1 (de) | Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften | |
WO2004019872A3 (en) | Oral delivery of modified transferrin fusion proteins | |
DK1539221T3 (da) | Transferrin-fusionsproteinbiblioteker | |
WO2006049983A3 (en) | Peptide yy modified transferrin fusion proteins | |
BR0212287A (pt) | Proteìna de ligação caspase-8, sua preparação e uso | |
EA200000875A1 (ru) | Белки, взаимодействующие с каспазой-8 | |
WO2008021412A3 (en) | Interferon beta and transferrin fusion proteins | |
HK1082510A1 (en) | Promoter to il-18bp, its preparation and use | |
WO2001002429A3 (en) | Angiopoietin-6 and uses thereof | |
ATE325873T1 (de) | Androgenrezeptor-komplex assoziiertes protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 13, 25 DA LPI |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |